KAPA logo

KAIROS PHARMA LTD

KAPANYSE AMERICAN
🏆 #5182 by market capEarnings Nov 13US Equity
$1.66▼ $0.04 (−2.35%)
After hours · at close
🔔
Track KAPA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.4%
7d▼ 7.3%
14d▼ 6.7%
30d▲ 1.7%
ytd▼ 66.7%
1y▼ 79.1%
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
80
Good

Trading Snapshot

Day Range
$1.65 – $1.69
52-Week Range
$1.51 – $9.59
Volume
$2.56B
Avg Volume
$2.81B
Shares Outstanding
3.1M
Next Earnings
Nov 27, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$267,946
P/E Ratio
-0.9
P/S Ratio
0.0x
EPS (TTM)
$-1.90
Dividend Yield
0.00%
Dilution (1yr)
+34.2%

Why Investors Own KAPA

  • ✓High-growth profile — revenue up +39.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 62% gross margin and 14% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

KAPA logo

KAIROS PHARMA LTD

KAPA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▲ +137.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −13.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.6M▲ +34.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▲ +$3M YoY
StockOtter · stockotter.space

About KAIROS PHARMA LTD

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Ratings

ⓘ
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Bloomberg·2h ago

KAIROS PHARMA LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift KAPA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

KAIROS PHARMA LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.